Since the beginning of time, infections have been a major cause of disability and death of humans in every part of the world. For centuries, little was known about what caused infection, how to prevent infection, or how to cure infection. With the discovery of sulfa and penicillin in the 1930s, the ability to fight infection became reality. During the next six decades, antimicrobials were developed to fight bacterial, fungal, and viral infections. It truly seemed as if the battle against infection was won, until the rapid and global spread of drug resistance began to threaten the effectiveness of all currently available antimicrobials. A new phase of the war against infection began, and the search for methods of reducing the spread of drug resistance began. Today, it is apparent that identifying the agents of infection, understanding how antimicrobials are targeted against specific infectious organisms, and practicing the judicious application of antimicrobials will help reduce the threat of continued escalation of antimicrobial resistance. Part 1 of this three-part series will provide an overview of how antimicrobials are designed to target specific agents of infection and how drug resistance develops. Parts 2 and 3 will examine individual antibacterial, antifungal, and antiviral agents and the recommendations for their appropriate use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00006416-200501000-00012 | DOI Listing |
Asian Pac J Cancer Prev
January 2025
All India Institute of Medical Sciences, Department of Biochemistry, Vijaypur, Jammu, India.
Doxorubicin, a widely used anthracycline antibiotic, has been a cornerstone in cancer chemotherapy since the 1960s. In addition to doxorubicin, anthracycline chemotherapy medications include daunorubicin, idarubicin, and epirubicin. For many years, doxorubicin has been the chemotherapy drug of choice for treating a broad variety of cancers.
View Article and Find Full Text PDFProbiotics Antimicrob Proteins
January 2025
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Research into the role of probiotics-often referred to as "living supplements"-in cancer therapy is still in its early stages, and uncertainties regarding their effectiveness remain. Relevantly, chemopreventive and therapeutic effects of probiotics have been determined. There is also substantial evidence supporting their potential in cancer treatment such as immunotherapy.
View Article and Find Full Text PDFExp Appl Acarol
January 2025
Faculty of Science, Department of Molecular Biology and Genetics, Mugla Sıtkı Koçman University, Mugla, Türkiye.
The Varroa destructor (hereafter referred to as Varroa) is a major pest of honeybees that is generally controlled using pyrethroid-based acaricides. However, resistance to these insecticides has become a growing problem, driven by the acquisition of knockdown resistance (kdr) mutations in the mite's voltage-gated sodium channel (vgsc) gene. Resistance mutations in the vgsc gene, such as the L925V mutation, can confer resistance to pyrethroids like flumethrin and tau-fluvalinate.
View Article and Find Full Text PDFExpert Rev Anticancer Ther
January 2025
Department of Pharmacy, Guru Ghasidas University, Bilaspur, C.G, India-, ().
Introduction: The synergistic combination of histone deacetylase inhibitors and platinum-based medicines represents a promising therapeutic strategy to efficacy and overcome drug resistance in cancer therapy, necessitating a comprehensive on their molecular interactions and clinical potential.
Areas Covered: The objective of presented review is to investigate the molecular pathways of platinum medicines and HDAC inhibitors. A comprehensive literature review from 2011 to 2024 was conducted across multiples databases like MEDLINE, PubMed, Google Scholar, Science Direct, Scopus and official websites of ClinicalTrial.
Microbiol Spectr
January 2025
Servei de Microbiologia i Parasitologia-CDB, Hospital Clínic de Barcelona, Barcelona, Spain.
Unlabelled: is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing has further complicated the management of nosocomial infections, limiting therapeutic options. Cefiderocol has recently emerged as a promising antipseudomonal agent, using the bacterial iron transport system to gain entry into the cell; however, there have been reports of resistant to cefiderocol.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!